GLP-1 News & Updates

Daily summaries of the most important GLP-1 stories — FDA decisions, clinical research, telehealth updates, and insurance coverage changes.

We independently review every GLP-1 program. No sponsored placements. No biased rankings.

Last updated: September 5, 2026

Today — Saturday, September 5, 2026

1 article

Endpoints News 9/5/2026 Market

Italy's Menarini Licenses European Rights to Chinese GLP-1 Drug Bofanglutide

Quick answer: Italy's Menarini Group signed an exclusive license agreement with China's Gan & Lee Pharmaceuticals for European rights to bofanglutide, a once-every-two-weeks GLP-1 receptor agonist for obesity and overweight. The deal is worth up to 726 million euros, including a 62 million euro upfront payment plus milestones, and covers 39 European markets including the EU, UK, and Switzerland.

Read the original at Endpoints News

Yesterday — Friday, September 4, 2026

4 articles

Medical Xpress 9/4/2026 Research

GLP-1 Prescriptions for Children Under 12 With Obesity Up 310-Fold Since 2019, Still Rare

Quick answer: An NYU Langone Health study published in Pediatrics found that prescriptions for Saxenda, Wegovy and Zepbound among U.S. children under 12 with obesity were 310 times higher in June 2026 than in 2019, though still only 0.6% of that group receive them, compared with 0.9% of adolescents ages 12 to 17. The numbers show pediatric use of these drugs is growing fast from a very small base at a time when long-term safety data in young children remains thin. Expect more scrutiny of prescribing guidelines as the trend continues.

Read the original at Medical Xpress

Fierce Pharma 9/4/2026 Insurance

Analyst Sees Blockbuster Lilly Sales From Medicare's $50-a-Month GLP-1 Bridge Program

Quick answer: Early uptake figures are in for Medicare's new "bridge" model, which offers weight-loss drugs to eligible seniors at $50 per month under the pricing deal the Trump administration struck with Eli Lilly and Novo Nordisk, and one analyst projects the program could translate into blockbuster annual sales for Lilly. For older adults, this is the first broad Medicare pathway to Wegovy and Zepbound for obesity itself rather than a related condition. How many seniors ultimately enroll, and how the program is funded long term, are still open questions.

Read the original at Fierce Pharma

MedPage Today 9/4/2026 Clinical

GLP-1 Use Is Spreading Into Dermatology, and So Are the Liability Questions

Quick answer: A medicolegal review finds that liability cases tied to GLP-1 prescribing in dermatology have been rare so far but deserve attention as more dermatologists prescribe the drugs. For patients, it is a reminder that GLP-1s are increasingly being prescribed outside endocrinology and primary care, and that off-label or cosmetic use raises its own consent and monitoring issues. The review urges careful documentation and patient counseling as use expands.

Read the original at MedPage Today

BioPharma Dive 9/4/2026 Market

AI Drug Startup Superluminal Raises $60M for Rare-Obesity Drug Targeting MC4R

Quick answer: Superluminal Medicines raised $60 million to move its first drug candidate, an MC4R activator for rare genetic forms of obesity, into human testing by the end of the year. The approach mirrors Rhythm Pharmaceuticals' Imcivree and is a bet that appetite-regulating targets beyond GLP-1 can carve out their own niche, with the company saying it could eventually test the drug in general obesity alongside GLP-1 medications. Initial trials will focus on conditions like Bardet-Biedl syndrome and hypothalamic obesity.

Read the original at BioPharma Dive

Thursday — Thursday, September 3, 2026

1 article

ABC News / Good Morning America 9/3/2026 Regulatory

Connecticut AG Reaches Settlement With Online Platform Over Bootleg GLP-1 Sales

Quick answer: Connecticut Attorney General William Tong announced a settlement with the international trade platform Made-in-China requiring it to stop hosting sellers of unapproved "research grade" semaglutide and tirzepatide to U.S. customers, with a penalty of up to $300,000 that is suspended after $30,000 if the company complies. The platform must now screen for and remove GLP-1 listings within five days of discovery. State officials and researchers have found these unapproved products can contain impurities, bacterial contamination, or inconsistent doses of active ingredient, and the settlement follows a similar case Tong brought against a Connecticut-based seller in 2025.

Read the original at ABC News / Good Morning America

Wednesday — Wednesday, September 2, 2026

1 article

Euronews 9/2/2026 Market

Novo Nordisk Launches Wegovy Pill in Germany, First EU Country

Quick answer: Novo Nordisk's oral Wegovy pill became available in German pharmacies starting September 1, making Germany the first country in the European Union to carry the tablet following its EU approval in July. The prescription-only pill uses the same active ingredient, semaglutide, as the injection and is priced roughly 170 to 280 euros per package depending on dose. The launch follows earlier rollouts in the US, UK, and UAE and sharpens Novo's oral competition with Eli Lilly's rival pill, Foundayo, as both companies race to expand access beyond weekly injections.

Read the original at Euronews

Tuesday — Tuesday, September 1, 2026

3 articles

STAT News 9/1/2026 Insurance

GLP-1 Costs Are Forcing Employers to Rethink Worker Health Coverage

Quick answer: STAT reports that soaring GLP-1 spending has become the leading force pushing employers to reconsider how they design workers' health coverage. That matters because employer plans are how most working-age Americans get weight loss medication covered — if at all — and mounting cost pressure tends to translate into tighter access. The piece also flags Medicaid cuts and ongoing 340B fights as compounding pressures on the system.

Read the original at STAT News

MedPage Today 9/1/2026 Clinical

GLP-1 Use Tied to Higher Gallbladder and Biliary Risks in Youth

Quick answer: A retrospective analysis of TriNetX data covering more than 37,000 adolescents and young adults with overweight or obesity found GLP-1 receptor agonist use was associated with increased cumulative gallbladder and biliary events. Gallbladder problems are a known adverse-event signal in adults, and this adds evidence the risk extends to younger patients as prescribing expands to that age group. As an observational study it shows association rather than cause, but it is worth raising with a prescriber.

Read the original at MedPage Today

MedPage Today 9/1/2026 Research

Studies Suggest GLP-1 Benefits May Extend to Infectious Disease Risk

Quick answer: Recent studies suggest people with type 2 diabetes taking GLP-1 receptor agonists were less likely to develop tuberculosis or to be hospitalized or die from infections, including an international analysis spanning more than 7 million people. It is another entry in the growing list of possible GLP-1 benefits beyond weight and blood sugar. These are observational findings, so randomized trials are needed before infection protection becomes part of the prescribing picture.

Read the original at MedPage Today

Monday — Monday, August 31, 2026

3 articles

SciTechDaily 8/31/2026 Clinical

GLP-1 Use Linked to Small Increase in Rare Optic Nerve Condition, Rutgers Study Finds

Quick answer: A Rutgers analysis published in Annals of Internal Medicine found that adults with type 2 diabetes taking GLP-1 medications had a slightly higher rate of ischemic optic neuropathy, a rare drop in blood flow to the optic nerve that can cause sudden and often permanent vision loss. The absolute increase was small, roughly three to four extra cases per 10,000 patients over 18 months, and most affected patients were men or adults aged 50 to 65. Researchers caution the link may reflect underlying health differences rather than the drugs themselves, but say sudden vision changes warrant prompt evaluation by an eye specialist.

Read the original at SciTechDaily

CNN 8/31/2026 Market

Seizures of Smuggled Weight-Loss Drugs Nearly Triple on Brazil-Paraguay Border

Quick answer: Brazilian customs officers seized more than 76,000 pens, vials and other semaglutide and tirzepatide products along the Paraguay border in the first half of 2026, close to triple the total for all of last year. Smugglers have shifted toward weight-loss drugs because the pens are small, high in value and far easier to move than traditional contraband, turning up hidden in boot soles, shampoo bottles and concealed car compartments. Because injectable GLP-1s require controlled refrigeration, medication that travels these routes may be degraded or unsafe by the time it reaches a patient.

Read the original at CNN

News-Medical 8/31/2026 Research

Review Finds No Evidence That Injection Day Affects GLP-1 Results

Quick answer: A systematic review published in Medicina screened 1,000 records and turned up only three studies touching on when in the week semaglutide or tirzepatide is injected, none of which directly compared one day against another. The limited indirect evidence suggests that choosing a day which fits a patient routine can support adherence and tolerability without compromising blood sugar control or weight loss. The authors are careful to frame this as absence of evidence rather than proof that every dosing day is equivalent, and emphasize that week-to-week consistency matters more than the specific day chosen.

Read the original at News-Medical

Sunday — Sunday, August 30, 2026

2 articles

Eli Lilly (Investor Relations) 8/30/2026 Clinical

Real-World Study: Zepbound Cuts Healthcare Costs for Adults Over 55

Quick answer: A retrospective claims analysis matching 15,843 adults over 55 who started Zepbound (tirzepatide) against untreated peers found monthly healthcare costs fell as much as 25% below the untreated group by 12-18 months of treatment, driven by fewer hospital admissions and ER visits. Savings appeared within six months (12-15% lower costs) and exceeded the price of the drug itself by the one-year mark, according to a study published in Diabetes, Obesity and Metabolism using claims data from November 2022 through September 2025.

Read the original at Eli Lilly (Investor Relations)

Fierce Pharma 8/30/2026 Market

Oral GLP-1 Tracker: Lilly's Foundayo Tops 40,000 Weekly Scripts, Still Trails Wegovy Pill

Quick answer: Twenty weeks into launch, Eli Lilly's oral obesity pill Foundayo topped 40,000 weekly prescriptions for the first time, posting 40,862 scripts, per IQVIA data cited in Fierce Pharma's ongoing tracker. That pace still trails Novo Nordisk's oral Wegovy, which hit roughly 57,000 scripts by its own sixth week and now accounts for 35% of total Wegovy prescriptions, showing the oral obesity-pill race remains Novo's to lose even as Lilly gains ground.

Read the original at Fierce Pharma

Saturday — Saturday, August 29, 2026

2 articles

Fierce Pharma 8/29/2026 Regulatory

Lilly Scores FDA Expansion for Mounjaro to Reduce Heart Attack and Stroke Risk

Quick answer: The FDA approved an expanded indication for Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of heart attack or stroke in at-risk adults with type 2 diabetes. The added cardiovascular indication narrows a key labeling gap with Novo Nordisk and gives insurers and prescribers a stronger clinical case for the drug beyond blood sugar control. Watch for whether the expanded label shifts formulary positioning against Novo's rival GLP-1s.

Read the original at Fierce Pharma

MedPage Today 8/29/2026 Clinical

About a Quarter of Those Who Stop Wegovy Start Again

Quick answer: A Danish cohort study of 157,822 first-time semaglutide users without diabetes found that 49% discontinued treatment within a year, and roughly a quarter of those who stopped later restarted. The findings show how common stop-and-restart cycles are in real-world GLP-1 use, underscoring that long-term adherence, not just starting the drug, is the central challenge for lasting weight outcomes.

Read the original at MedPage Today

Monday — Monday, August 24, 2026

2 articles

Axios 8/24/2026 Regulatory

Unapproved Obesity Drug Retatrutide Spawns a Black Market Frenzy

Quick answer: Despite not being FDA-approved and not even submitted for review until next year, Eli Lilly's experimental triple agonist retatrutide is being sold by dozens of vendors online under names like "r3ta," some labeled "research use only" while clearly marketed for human use. Lilly has filed six lawsuits against med spas, a compounding pharmacy, and other vendors, and is pushing payment processors and social platforms to cut off the sellers as the FDA issues warning letters.

Read the original at Axios

Marketplace 8/24/2026 Insurance

Fewer Employers Are Covering GLP-1 Drugs for Weight Loss. Should They?

Quick answer: Only about a third of employers cover GLP-1 drugs for obesity, and Cigna data cited in the report shows roughly 6% of large employers dropped weight-loss coverage in 2026 as costs climbed. The story contrasts holdouts like Bank of America, which spends about $250 million a year covering GLP-1s plus lifestyle coaching, with workers who face hundreds or thousands of dollars a month out of pocket when their plan does not cover the drugs.

Read the original at Marketplace

Friday — Friday, August 28, 2026

4 articles

Law360 8/28/2026 Regulatory

Appeals Court Backs FDA and Drugmakers in Fight Over Compounded GLP-1s

Quick answer: A federal appeals court ruled the FDA acted lawfully when it removed semaglutide and tirzepatide from the national drug shortage list, rejecting compounding pharmacies' argument that the move required formal notice-and-comment rulemaking. The decision closes off the main legal path compounders had for continuing to mass-produce cheaper copies of Wegovy, Ozempic, Zepbound, and Mounjaro. Patients still using compounded versions may see remaining suppliers exit the market faster.

Read the original at Law360

Fierce Pharma 8/28/2026 Policy

PhRMA's Medicare Price Negotiation Suit Rebuffed in Latest Blow to Industry IRA Challenge

Quick answer: The Fifth Circuit upheld a lower-court ruling against PhRMA's lawsuit challenging Medicare's drug price negotiation program, reasoning that drugmaker participation in Medicare is voluntary. Courts have now consistently rejected the industry's constitutional challenges to the program, which selected Ozempic, Rybelsus, and Wegovy for its second round of negotiations, with lower prices set to take effect in 2027.

Read the original at Fierce Pharma

Reuters 8/28/2026 Market

China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy

Quick answer: Novo Nordisk said China's drug regulator accepted its application to sell the oral version of Wegovy, its once-daily semaglutide pill. China is the world's second-largest pharmaceutical market, and Novo is racing Eli Lilly, Pfizer, and local firms for share of a fast-growing obesity market as it tries to repeat the pill's strong U.S. launch. No approval timeline has been announced.

Read the original at Reuters

CalMatters 8/28/2026 Policy

Can't Afford Ozempic? A New California Bill Wants to Change That

Quick answer: California's Senate Bill 1089, nearing final approval in Sacramento, would direct the state to pursue a partnership with a drug manufacturer through its CalRx program to drive down GLP-1 prices. Most insurers in the state still don't cover the drugs for weight loss, leaving out-of-pocket costs beyond reach for many patients. The bill now heads toward a final vote and the governor's desk.

Read the original at CalMatters

Wednesday — Wednesday, August 26, 2026

2 articles

NPR 8/26/2026 Insurance

Drugstores Say Medicare's $50 Obesity Drug Program Is Catching On

Quick answer: CVS and Walgreens each tell NPR they have filled roughly 100,000 prescriptions under Medicare's new Bridge program, which lets some beneficiaries get obesity drugs for $50 a month. Less than two months after its July 1 launch, early volume suggests real demand among the nearly 4 million eligible beneficiaries, with total program costs projected between $1.3 billion and $10 billion depending on participation. The program runs through 2027 and excludes beneficiaries with sleep apnea or type 2 diabetes, since Part D should already cover GLP-1s for those conditions.

Read the original at NPR

Truveta 8/26/2026 Research

Johns Hopkins-Led Study Earns NIH Grant to Track Long-Term GLP-1 Outcomes

Quick answer: The NIH's National Institute of Diabetes and Digestive and Kidney Diseases awarded a five-year R01 grant to a Johns Hopkins Bloomberg School of Public Health team to study semaglutide and tirzepatide using Truveta's real-world data linked to millions of de-identified insurance claims. The study aims to generate evidence on GLP-1 drugs' long-term health outcomes, healthcare costs, and patient access. Findings could shape how payers and regulators weigh the drugs' long-term value.

Read the original at Truveta

Thursday — Thursday, August 27, 2026

4 articles

MedPage Today 8/27/2026 Clinical

GLP-1 Drugs Could Help Narrow Lifespan Gap in Serious Mental Illness

Quick answer: A large target trial emulation found that adults with serious mental illness who started a GLP-1 receptor agonist had significantly lower risks of death and cardiovascular events. Cardiovascular disease is a leading driver of the shortened lifespans seen in this population, so the findings point to a group that may benefit disproportionately from these drugs. As observational data, the results will need confirmation in prospective trials.

Read the original at MedPage Today

MedPage Today 8/27/2026 Clinical

GLP-1s May Offer Benefit in Ulcerative Colitis, Real-World Data Suggest

Quick answer: A retrospective cohort study of 300 patients with ulcerative colitis linked GLP-1 receptor agonist use to improved remission rates. It adds to growing evidence that GLP-1s may carry anti-inflammatory effects beyond weight loss and blood sugar control. The study is small and observational, so controlled trials would be needed before this changes practice.

Read the original at MedPage Today

BioPharma Dive 8/27/2026 Market

Zepbound May Cut Healthcare Costs, Real-World Study Says

Quick answer: A new real-world study suggests Zepbound use could reduce rates of hospital stays and emergency room visits. Evidence that GLP-1s lower downstream healthcare costs strengthens the case employers and insurers weigh when deciding whether to cover the drugs. Expect payers and manufacturers to lean on this kind of data as coverage debates intensify.

Read the original at BioPharma Dive

STAT News 8/27/2026 Insurance

About 14% of U.S. Employers Have Dropped or Plan to Drop GLP-1 Coverage in 2027

Quick answer: STAT reports that about 14% of U.S. employers have already dropped or plan to drop coverage of GLP-1 drugs in 2027 as health costs climb. Employer plans are one of the main routes to affordable access, so a coverage retreat could push more patients toward cash-pay and telehealth programs. It follows recent projections of 9.5% employer health-cost growth in 2027 with GLP-1 spending a named driver.

Read the original at STAT News

Tuesday — Tuesday, August 25, 2026

4 articles

KFF Health News 8/25/2026 Insurance

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Do Not Qualify

Quick answer: The new Medicare GLP-1 Bridge program promises eligible beneficiaries weight loss drugs for as little as $50 a month, but some patients are excluded because they have the very conditions these drugs are approved to treat. For seniors counting on the discount, a qualifying diagnosis can paradoxically shut the door on affordable access. How CMS handles coverage exceptions for these patients remains unsettled.

Read the original at KFF Health News

Houston Chronicle 8/25/2026 Regulatory

Copycat GLP-1 Drugs Are Cheaper. But Here Is What You Need to Know

Quick answer: Compounding pharmacies can no longer legally copy brand-name GLP-1s, yet many keep selling personalized versions mixed with vitamins or at nonstandard doses that sidestep the FDA approval process. By one industry estimate roughly two million patients have taken compounded GLP-1s, and the FDA has flagged safety concerns because these products are not reviewed for quality. Anyone weighing a cheaper compounded option should understand exactly what they are getting and from whom.

Read the original at Houston Chronicle

Fierce Pharma 8/25/2026 Research

Novo Kicks Off Trial Testing Smaller Doses of Wegovy Pill

Quick answer: Just eight months after introducing its Wegovy pill, Novo Nordisk has launched the phase 3 OASIS 5 study testing the oral GLP-1 at smaller doses. More dose options could broaden who can start or stay on the pill, particularly patients who struggle with tolerability at current doses. Results will shape how flexible oral semaglutide dosing becomes.

Read the original at Fierce Pharma

Fierce Pharma 8/25/2026 Market

Lilly Covers Lifelong Obesity Journey in New GLP-1 Medicaid Access Campaign

Quick answer: Eli Lilly launched a Medicaid access campaign anchored by A Life Covered, a short film following one woman's decades-long weight loss journey, and it deliberately brings older adults into the obesity conversation. The push signals how hard manufacturers are lobbying to expand government coverage of GLP-1s as state Medicaid programs weigh costs. Whether the campaign moves actual coverage decisions is the open question.

Read the original at Fierce Pharma

Saturday — Saturday, August 22, 2026

3 articles

Aon 8/22/2026 Insurance

Employer Health Costs Projected to Rise 9.5% in 2027, With GLP-1 Spending a Named Driver

Quick answer: Aon projects US employer health care costs will climb 9.5% in 2027, pushing average spending past $19,000 per employee and marking a fourth straight year of near-double-digit increases. Aon points to greater use of specialty medicines and GLP-1 treatments as part of what is driving prescription costs higher. For people who get their coverage through work, this is the pressure that shapes next year's formulary rules, prior-authorization requirements, and cost-sharing for weight-loss drugs.

Read the original at Aon

Yahoo Health 8/22/2026 Clinical

Obesity Specialists Push Back on GLP-1 Microdosing, Citing Thin Evidence

Quick answer: Obesity medicine clinicians say there is little to no peer-reviewed evidence supporting microdosed GLP-1 regimens, because those schedules fall outside what the approval trials actually studied. The concern is not that smaller doses are inherently wrong but that unsupervised microdosing carries real risks including undertreatment, dosing errors, and contamination when drugs are sourced outside normal channels. Clinicians do sometimes use lower doses, but under medical supervision rather than as a self-directed workaround for cost or side effects.

Read the original at Yahoo Health

BioPharma Dive 8/22/2026 Market

Cost and Patient Perception May Decide the Next Phase of the GLP-1 Market

Quick answer: As Eli Lilly and Novo Nordisk compete for share of the obesity drug market, survey data suggests affordability and prescriber preference may matter more than head-to-head efficacy in determining who wins. That is a meaningful shift for patients, because it points toward price competition and broader access rather than a market decided purely on trial results. How aggressively either company moves on pricing is still an open question.

Read the original at BioPharma Dive

Friday — Friday, August 21, 2026

2 articles

Fierce Pharma 8/21/2026 Market

Novo Nordisk Launches Phase 3 Trial Testing Lower Maintenance Doses of the Wegovy Pill

Quick answer: Novo Nordisk has begun OASIS 5, a placebo-controlled phase 3 study testing whether maintenance doses of the Wegovy pill below the approved 25 mg still produce meaningful weight loss. The 450-patient trial runs 60 weeks across the United States and Europe, and Novo has not disclosed which two lower strengths it is evaluating. If lower doses hold up, they could offer a cheaper and better-tolerated way to stay on treatment long term, something patients have already been improvising through unapproved microdosing and compounded products.

Read the original at Fierce Pharma

ABC News 8/21/2026 Research

Researchers Begin Testing Whether GLP-1 Drugs Slow Biological Aging

Quick answer: Researchers at the University of Texas Medical Branch are running one of the first clinical trials built specifically to test whether tirzepatide affects biological aging, following adults aged 55 to 70 and tracking inflammation, cognitive function, strength and mobility. The work builds on an earlier randomized, placebo-controlled trial in which adults with HIV showed slower aging across several DNA-based aging clocks after 32 weeks on semaglutide. Investigators are explicit that there is no evidence yet that healthy people should take a GLP-1 for longevity.

Read the original at ABC News

Wednesday — Wednesday, August 19, 2026

2 articles

BioPharma Dive 8/19/2026 Research

Amylyx's bet on a GLP-1 blocker pays off

Quick answer: Amylyx reported that a late-stage trial of avexitide, a first-in-class GLP-1 receptor antagonist, met its primary endpoint of reducing episodes of low blood sugar in people who had undergone bariatric surgery. The drug works in the opposite direction from Ozempic and Wegovy, blunting GLP-1 signaling rather than amplifying it, to treat post-bariatric hypoglycemia. Amylyx picked up the program cheaply in a bankruptcy auction, and the result is the clearest sign yet that blocking GLP-1 has real therapeutic uses of its own.

Read the original at BioPharma Dive

MedPage Today 8/19/2026 Clinical

GLP-1s and Birth Control; Retatrutide Lawsuits; Air Pollution and Menopause

Quick answer: MedPage Today's endocrinology roundup highlights reporting that GLP-1 medications may reduce the effectiveness of birth control pills, alongside early litigation involving retatrutide. The contraception question matters for anyone of reproductive age starting a GLP-1, since these drugs slow stomach emptying and can change how oral medications are absorbed. The roundup points to outside reporting rather than a single new trial, so it is worth raising with a prescriber rather than treating as settled.

Read the original at MedPage Today

Monday — Monday, August 17, 2026

1 article

Fierce Pharma 8/17/2026 Market

Novo Nordisk Seeks Preliminary Injunction to Halt Eli Lilly's Comparative GLP-1 Ads

Quick answer: A New Jersey federal court is set to hear Novo Nordisk's motion for a preliminary injunction against Eli Lilly on August 17, part of a lawsuit Novo filed in July accusing Lilly of false advertising. Novo alleges Lilly's Zepbound and Mounjaro campaigns compare against outdated, lower approved doses of Wegovy and Ozempic while omitting newer, higher-dose data now on the market. Lilly has rejected the claims as untrue and says it does not plan to change the ads, setting up a contested hearing over how GLP-1 drugmakers can market head-to-head efficacy claims.

Read the original at Fierce Pharma

Tuesday — Tuesday, August 18, 2026

2 articles

STAT News 8/18/2026 Research

A Pill That Mimics Exercise? Early Results on Drug Designed to Maintain Both Weight Loss and Muscle Mass

Quick answer: Colorado biotech Enveda reported preliminary first-in-human results for ENV-308, an experimental once-daily oral drug meant to help people hold onto weight loss — and muscle — after GLP-1 treatment. It is being positioned as a maintenance therapy alongside or after semaglutide and tirzepatide rather than a replacement, aimed squarely at the biggest unanswered question in GLP-1 care: what happens when you stop. The data is early-stage and the company is careful not to call it exercise in a pill, so how much this matters for patients depends on much larger trials still to come.

Read the original at STAT News

MedPage Today 8/18/2026 Clinical

Obesity Drugs Show Early Promise Against PMOS, the Hormonal Disorder Formerly Known as PCOS

Quick answer: A small but growing body of research is testing GLP-1 medications against PMOS — the condition renamed from polycystic ovary syndrome earlier this year — with early studies pointing to improvements in insulin resistance, hormone balance and ovulation, not just weight. Most women with PMOS have insulin resistance, and high insulin can drive the ovaries to produce more testosterone, which is the proposed mechanism behind symptoms like skipped periods, severe acne and unwanted hair growth. The trials so far are small and early, but PMOS affects roughly one in eight women, so a treatment that works on the underlying insulin problem would be a meaningful shift in care.

Read the original at MedPage Today

Sunday — Sunday, August 16, 2026

1 article

Novo Nordisk / AWS (press release) 8/16/2026 Market

Novo Nordisk and AWS Announce Strategic Partnership to Accelerate AI-Driven Drug Discovery

Quick answer: Novo Nordisk named Amazon Web Services its preferred cloud provider and strategic AI partner on August 10, opening a co-innovation hub in London where scientists will use tools such as Amazon Bio Discovery and Bedrock AgentCore to speed drug discovery, including within its GLP-1 pipeline. The companies say the partnership also targets efficiency gains across Novo's commercial operations and IT, with early pilots already cutting clinical documentation time for some of the company's 25,000-plus employees using the tools. The deal underscores how the leading GLP-1 makers are leaning on AI to compress R&D timelines as competition with Eli Lilly intensifies.

Read the original at Novo Nordisk / AWS (press release)

Saturday — Saturday, August 15, 2026

3 articles

Fierce Pharma 8/15/2026 Market

The Oral GLP-1 Tracker: Novo's Wegovy pill struggles to break through market share ceiling

Quick answer: Fierce Pharma has launched a weekly Oral GLP-1 Tracker that uses analyst notes and IQVIA prescription data to follow how Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo are splitting the new oral weight-loss market. The early read is that the Wegovy pill is having trouble pushing past a market share ceiling against its rival. For patients, the competition between these two pills is what will shape pricing and pharmacy availability over the coming year.

Read the original at Fierce Pharma

Drug Topics 8/15/2026 Policy

The 2026 GLP-1 Compounding Crackdown: A Pharmacist's Guide

Quick answer: Drug Topics lays out a paradox in pharmacy practice this year: brand-name semaglutide and tirzepatide supply has stabilized and the shortages that opened the door to mass compounding are over, yet the compounded GLP-1 market is still going strong. Cheap direct-to-consumer offers keep pulling patients toward compounded versions even though the branded drugs are back in stock, leaving pharmacists to handle the safety and regulatory fallout. Anyone weighing a low-cost compounded option should understand it no longer rests on the shortage-era legal footing it once did.

Read the original at Drug Topics

Medical Xpress 8/15/2026 Research

Researchers Examine Unanticipated Benefits of GLP-1 Medications

Quick answer: A review in the journal Obesity, co-authored by Dr. Steven Heymsfield of Pennington Biomedical Research Center and Dr. Adam Gilden of the University of Colorado, gathers evidence that GLP-1 medications may reduce inflammation and lower the risk of certain cardiovascular and musculoskeletal conditions. Early studies also point to reduced alcohol consumption and lower risk of some substance use disorders, though the authors are clear that dedicated clinical trials are still needed to confirm those effects. Their overall conclusion is that the evidence so far supports a favorable risk-benefit profile for GLP-1 receptor agonists and dual agonists.

Read the original at Medical Xpress

Friday — Friday, August 14, 2026

2 articles

Fierce Pharma 8/14/2026 Market

Novo CEO Says Obesity Drug Market Won't Be a Zero-Sum Game With Lilly

Quick answer: In an August 13 Reuters interview, Novo Nordisk CEO Mike Doustdar pushed back on the idea that the GLP-1 market is a winner-take-all fight with Eli Lilly, saying patients increasingly weigh tolerability, dosing form (pill vs. injection), and the quality of weight loss rather than just picking the single most potent drug. For consumers, that signals more differentiated options are coming as newer medicines reach the market rather than one drug dominating on efficacy alone. Novos own oral pill strategy is central to that bet as it competes with Lillys injectables and pipeline.

Read the original at Fierce Pharma

MedPage Today 8/14/2026 Clinical

Preoperative GLP-1 Use Does Not Reduce Bariatric Surgery Weight Loss, UCSF Study Finds

Quick answer: A UCSF retrospective review of 383 bariatric surgery patients found no meaningful gap in one-year weight loss between those who had taken a GLP-1 medication beforehand (24% of total body weight lost) and those who had not (25%), with no differences in diabetes control, complications, hospital stay, or ER visits either. That is reassuring for the growing number of patients using GLP-1s as a bridge to surgery, since researchers had worried preoperative use might blunt the post-op weight-loss response. The findings support treating drugs and surgery as complementary options rather than competing ones.

Read the original at MedPage Today

Thursday — Thursday, August 13, 2026

3 articles

AllSci 8/13/2026 Regulatory

United Laboratories Wins FDA Clearance to Begin US Trials of Oral GLP-1 Pill

Quick answer: China-based United Laboratories announced FDA clearance of its investigational new drug application for UBT48128, a small-molecule oral GLP-1 receptor agonist for obesity and type 2 diabetes, moving the drug from preclinical work into early-stage US human trials. The oral, non-injectable format adds another contender to the crowded GLP-1 pill race alongside Eli Lillys orforglipron and Novo Nordisks oral semaglutide, though UBT48128 is still years from a possible approval. The companys preclinical superiority claims over existing drugs have not yet been tested in humans.

Read the original at AllSci

ScienceDaily / Northwestern Medicine 8/13/2026 Research

New Oral GLP-1 Pill Shows Up to 12% Weight Loss in Phase 2 Trial

Quick answer: A phase 2b trial published in Nature Medicine found that aleniglipron, an experimental once-daily oral small-molecule GLP-1 drug, helped adults with obesity lose up to 12.1% of body weight over 36 weeks at the highest of three tested doses. Unlike injectable GLP-1 drugs, aleniglipron does not require refrigeration, which researchers say could make it easier to manufacture and distribute at scale if later trials confirm its safety and effectiveness. Gastrointestinal side effects were common but mostly mild, and the drug is now advancing to a phase III trial.

Read the original at ScienceDaily / Northwestern Medicine

Chain Drug Review 8/13/2026 Insurance

Survey: Employers Increasingly Lean on PBMs to Manage Soaring GLP-1 Costs

Quick answer: A new CVS Caremark survey found that 77% of employers are concerned about the cost of covering GLP-1 weight-loss drugs, and 80% have already limited coverage or are considering doing so. Most employers say pharmacy benefit managers are best positioned to control these costs through formulary strategy, biosimilar substitution, and utilization management programs. The findings show commercial insurers and employers, not just Medicare and Medicaid, are actively tightening GLP-1 access as demand and prices keep climbing.

Read the original at Chain Drug Review

Wednesday — Wednesday, August 12, 2026

3 articles

Fierce Pharma 8/12/2026 Market

Lilly Sues Six Companies Over Black-Market Sales of Retatrutide

Quick answer: Eli Lilly filed lawsuits against six U.S. companies -- a California medical spa chain and five Texas peptide sellers -- accusing them of illegally selling black-market retatrutide, Lilly's investigational triple-hormone obesity drug that remains in Phase 3 trials and unapproved by the FDA. Lilly says it has reported more than 200 entities and over 14,000 websites, ads, and listings peddling the drug to regulators and law enforcement, following an FDA warning this spring about the safety risks of unapproved copycat GLP-1 drugs. The case underscores that anything sold as retatrutide outside a clinical trial is unverified and carries real health risk, whatever the marketing claims.

Read the original at Fierce Pharma

News-Medical.net 8/12/2026 Research

SELECT Trial Sub-Analysis Links Semaglutide to Lower Dementia-Risk Biomarker

Quick answer: A post hoc analysis of Novo Nordisk's SELECT cardiovascular trial, published in Alzheimer's & Dementia in August 2026, found that two years of semaglutide (Wegovy) slowed the rise of a 25-protein blood signature that predicts future dementia risk in older adults with cardiovascular disease and overweight or obesity, versus placebo -- corresponding to a 26.0% lower modeled 5-year dementia risk and an 8.8% lower modeled 20-year risk. It's a biomarker signal from a trial that wasn't designed to track cognition, not a confirmed drop in diagnosed dementia cases, and the study was funded by Novo Nordisk with two co-authors as company employees. Researchers say the next step is testing whether the biomarker shift actually translates into less cognitive decline.

Read the original at News-Medical.net

MedPage Today 8/12/2026 Provider

U.S. News Releases First-Ever Ratings of GLP-1 Telehealth Platforms

Quick answer: U.S. News & World Report published its debut ratings of GLP-1 telehealth platforms on August 12, evaluating 20 online providers that prescribe FDA-approved, brand-name GLP-1 medications such as Wegovy, Zepbound, Ozempic, and Foundayo. It's the first time the outlet has scored this category, giving consumers a more structured way to compare platforms on clinical rigor and patient satisfaction rather than price alone. The ratings arrive as the GLP-1 telehealth market keeps expanding and platform quality varies widely, making third-party comparisons increasingly useful for people weighing where to start treatment.

Read the original at MedPage Today

Tuesday — Tuesday, August 11, 2026

2 articles

STAT News 8/11/2026 Insurance

Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs

Quick answer: A STAT News opinion piece by physician Jeffrey Millstein argues that Medicare's new GLP-1 Bridge program, which launched July 1, 2026 offering Wegovy, Zepbound, and Foundayo at a $50 monthly copay, is bogged down by administrative and eligibility hurdles that could keep eligible seniors from actually using it. Millstein warns the friction risks undermining confidence in GLP-1 coverage broadly, right as CMS is trying to expand access. The Bridge program runs through December 2027, so how it's implemented in the coming months will shape whether Medicare's wider GLP-1 coverage push succeeds.

Read the original at STAT News

FoodNavigator.com 8/11/2026 Clinical

GLP-1s could be linked to more than 150 deaths

Quick answer: UK regulator MHRA's Yellow Card adverse-event database now lists 153 suspected deaths linked to GLP-1 drugs: 37 tied to semaglutide, 18 to liraglutide, and 98 to tirzepatide, alongside thousands of reports of gastrointestinal and nervous-system side effects. MHRA and reporting outlets stress the data reflects suspected associations reported by patients and clinicians, not confirmed causation, since Yellow Card entries are not independently verified. The figures add to ongoing safety monitoring of GLP-1s as global usage scales, and will likely fuel calls for closer post-market surveillance.

Read the original at FoodNavigator.com

Monday — Monday, August 10, 2026

2 articles

MHRA (gov.uk) 8/10/2026 Regulatory

UK Becomes First in Europe to Authorise Orforglipron, Lilly's Daily Weight-Loss Pill

Quick answer: The UK medicines regulator authorised orforglipron, sold as Foundayo, for weight management in adults with a BMI of 30 or above (or 27 and above with a weight-related condition) and for glycaemic control in type 2 diabetes. It is the first small-molecule GLP-1 taken as a once-daily tablet to be cleared anywhere in Europe. The MHRA said it will keep the safety and effectiveness of the drug under close review, and the tablet is not yet available on the NHS pending a NICE assessment.

Read the original at MHRA (gov.uk)

News-Medical 8/10/2026 Research

Real-World Study Links Tirzepatide to Lower Heart Attack and Cardiovascular Event Risk

Quick answer: A population-based cohort study in The BMJ followed 52,971 US adults with type 2 diabetes and existing atherosclerotic cardiovascular disease, comparing those who started tirzepatide with those who started sitagliptin. At one year, major adverse cardiovascular events occurred in 2.9 percent of tirzepatide patients versus 4.4 percent on sitagliptin, with heart attack risk about a third lower. Because the data come from insurance claims rather than a randomised trial, the findings show an association rather than proof of cause.

Read the original at News-Medical

Sunday — Sunday, August 9, 2026

1 article

Fierce Pharma 8/9/2026 Market

Novo Nordisk Makes Omnicom Agency of Record for US Media Buying

Quick answer: Novo Nordisk has named Omnicom as its agency of record for U.S. media buying, ending a six-year relationship with WPP's Wavemaker. The switch puts a new team in charge of how Novo buys advertising for Wegovy and Ozempic at a moment when the company is fighting to hold market share against Eli Lilly's Zepbound and oral rivals. It's an agency-side change rather than a product or pricing move, so GLP-1 users likely won't notice anything directly, but it signals Novo is retooling its marketing operation as competition intensifies.

Read the original at Fierce Pharma

Saturday — Saturday, August 8, 2026

3 articles

STAT News 8/8/2026 Regulatory

Federal Judge Dismisses Compounding Pharmacy's Antitrust Suit Against Lilly and Novo Nordisk

Quick answer: A federal judge dismissed an antitrust lawsuit that a compounding pharmacy had brought against Eli Lilly and Novo Nordisk, according to STAT News. The ruling is the latest legal setback for compounders challenging the two GLP-1 makers as they defend patents and prescribing practices around Zepbound, Mounjaro, Ozempic, and Wegovy. It adds to a string of recent regulatory and legal actions narrowing the space for compounded semaglutide and tirzepatide alternatives.

Read the original at STAT News

Fierce Pharma 8/8/2026 Market

Lilly's Zepbound Remains Physicians' Favorite, Even as Oral Obesity Launches Alter Landscape

Quick answer: A new survey of healthcare specialists by Spherix Global Insights found that injectable GLP-1 drugs are still strongly preferred over newer oral options, with Eli Lilly's Zepbound the clear physician favorite. That's notable given recent launches of oral obesity pills like Novo Nordisk's Wegovy tablet and Lilly's Foundayo, which have so far struggled to shift physician habits despite their convenience advantage. It suggests injectables will keep dominating new prescriptions in the near term even as oral options expand access.

Read the original at Fierce Pharma

Fierce Pharma 8/8/2026 Market

Novo Nordisk's CFO Reflects on 'Roller Coaster' Pressure to Drive Growth

Quick answer: In an interview timed to Novo Nordisk's Q2 earnings release, CFO Karsten Munk Knudsen described the company's recent financial run as a 'roller coaster' and acknowledged the pressure to reignite growth after a tougher stretch for Wegovy and Ozempic sales. He pointed to pipeline candidate CagriSema as a reason for continued optimism. The comments offer a window into how Novo's leadership is framing its competitive response to Lilly heading into the back half of 2026.

Read the original at Fierce Pharma

Friday — Friday, August 7, 2026

3 articles

BioPharma Dive 8/7/2026 Market

Lilly climbs, Novo falls as obesity drug battle intensifies

Quick answer: Eli Lilly's stock climbed while Novo Nordisk's fell after Q2 2026 earnings showed Lilly's injectable GLP-1 franchise beating analyst expectations, while Novo posted a research disappointment and missed sales targets for its oral Wegovy pill. The diverging results underscore how competitive the oral and injectable obesity-drug race has become between the two market leaders. Investors will be watching whether Novo's oral Wegovy can regain momentum in the second half of 2026.

Read the original at BioPharma Dive

Fierce Pharma 8/7/2026 Market

Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow

Quick answer: Novo Nordisk's CEO expressed confidence the company's share price will eventually recover, pointing to continued strong sales of oral Wegovy as evidence the obesity-pill strategy is working. The oral formulation appears to be adding new patients rather than simply cannibalizing the injectable version, a metric investors are watching closely. The comments come as Novo works to reassure the market after a rocky earnings stretch.

Read the original at Fierce Pharma

GoodRx 8/7/2026 Research

Orforglipron vs. Tirzepatide: What Are the Major Differences?

Quick answer: GoodRx published an updated side-by-side comparison of orforglipron, the FDA-approved oral small-molecule GLP-1 medication, and tirzepatide, the injectable dual GIP/GLP-1 drug sold as Zepbound. The comparison walks through differences in weight-loss efficacy, dosing convenience, and administration route that patients and prescribers are weighing as oral GLP-1 options expand. As more oral options reach the market, this kind of drug-to-drug comparison is becoming a more common resource for people choosing between treatments.

Read the original at GoodRx

Thursday — Thursday, August 6, 2026

2 articles

Fierce Pharma 8/6/2026 Market

Lilly's obesity pill Foundayo disappointed in Q2, as injectables continue to boom

Quick answer: Eli Lilly reported $98 million in second-quarter sales for Foundayo (orforglipron), its newly launched once-daily oral GLP-1 pill, a slower start than hoped that trails Novo Nordisk's rival oral Wegovy pill. Lilly's injectable obesity drugs, Zepbound and Mounjaro, again outperformed analyst expectations, so the company's overall GLP-1 business remains strong even as the new pill finds its footing. The early sales gap raises questions about how quickly patients and prescribers will shift from injectable to oral GLP-1 options as more pills reach pharmacies this year.

Read the original at Fierce Pharma

Forbes Health 8/6/2026 Market

The Most Affordable GLP-1 Providers in 2026

Quick answer: Forbes Health refreshed its guide ranking the most affordable GLP-1 weight-loss providers for 2026, weighing subscription and cash-pay pricing alongside care quality. The guide urges patients to prioritize providers that perform a full medical evaluation and order appropriate labs rather than prescribing straight from a quick intake form, and to be wary of services advertising unusually low prices or no follow-up care. For GLP-1 shoppers comparing options, the update is a reminder that the lowest listed price isn't always the best overall value once safety and support are factored in.

Read the original at Forbes Health

Wednesday — Wednesday, August 5, 2026

3 articles

Endpoints News 8/5/2026 Market

Novo Nordisk and Eli Lilly report Q2 earnings as Wegovy pill outsells Lilly's new Foundayo

Quick answer: Novo Nordisk and Eli Lilly are reporting second-quarter earnings this week, putting the obesity-drug duopoly's rivalry back in focus — including the new race between oral GLP-1 pills, where Novo's Wegovy pill is currently outselling Lilly's recently launched Foundayo (orforglipron). Lilly reports on August 5, with investors watching Foundayo's early commercial performance alongside continued Zepbound and Mounjaro growth. The results offer the clearest read yet on how intensifying competition and new oral options are reshaping the fast-growing weight-loss market that GLP-1 patients rely on.

Read the original at Endpoints News

MedPage Today 8/5/2026 Clinical

ADA reviews annual-meeting police incident as obesity-drug scrutiny grows

Quick answer: The American Diabetes Association said its Audit and Governance Committee is reviewing an incident at this year's annual meeting, when five prominent experts were removed by police, and is preparing recommendations. MedPage Today's endocrinology roundup also flags an ongoing obesity-drug trial lawsuit and expanded early access to Eli Lilly's investigational retatrutide. Together, the items underscore the mounting governance and legal scrutiny surrounding the obesity-medicine field as GLP-1 use continues to expand.

Read the original at MedPage Today

GoodRx 8/5/2026 Market

Orforglipron vs. tirzepatide: how Lilly's new weight-loss pill compares to the injection

Quick answer: With Eli Lilly's orforglipron (Foundayo) now available as a once-daily GLP-1 pill for weight loss, GoodRx breaks down how it stacks up against tirzepatide, the once-weekly injection sold as Zepbound and Mounjaro. The key differences: orforglipron is an oral small molecule that targets GLP-1 alone, while tirzepatide is injectable and also activates GIP — a dual mechanism that research suggests may drive greater weight loss. The comparison helps patients weigh convenience against potential effectiveness as oral options reach the market.

Read the original at GoodRx

Stay Informed

Get the GLP-1 Insider Brief

Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.

No spam. Unsubscribe any time.